| Literature DB >> 35324589 |
Abdikarim Hussein Mohamed1, Nasteho Mohamed Sheikh Omar1, Marian Muse Osman1, Hussein Ali Mohamud1, Aşır Eraslan1, Metin Gur1.
Abstract
BACKGROUND: Widespread and rapidly emerging multidrug-resistant uropathogens, particularly carbapenem-resistant pathogens, are a public health concern that impairs the determination of empirical therapy. This study aims to evaluate the antimicrobial susceptibility profile and factors associated with catheter-associated urinary tract infection (CA-UTI).Entities:
Keywords: catheter-associated UTI; intensive care unit; multidrug-resistant
Year: 2022 PMID: 35324589 PMCID: PMC8948891 DOI: 10.3390/tropicalmed7030042
Source DB: PubMed Journal: Trop Med Infect Dis ISSN: 2414-6366
Factors associated with CA-UTI caused by MDR-uropathogens.
| Factors | MDR | 95% CI | ||
|---|---|---|---|---|
| Yes | No | |||
| Age | 0.893–2.010 | |||
| Gender | 0.643–1.263 | |||
| Site of admission | 1.124–5.600 | |||
| Catheter | 0.743–1.929 | |||
| Duration of catheterization | 0.644–4.195 | |||
| Comorbidities | 0.953–2.617 | |||
| Length of hospital stay (LOS) | 0.117–3.084 | |||
Distribution of uropathogens that showed bacterial growth including ESBL and MDR pathogens.
| Type of Microorganisms | No. Patients | Percentage |
|---|---|---|
| Gram-negative pathogens | 88 | 88.9% |
| 26 | 26.3% | |
| 13 | 13.1% | |
| 24 | 24.3% | |
| 19 | 19.2% | |
| 3 | 3% | |
| 1 | 1% | |
| 1 | 1% | |
| 1 | 1% | |
| Gram-positive pathogens | 11 | 11.1% |
| 9 | 9.1% | |
| 2 | 2% | |
| Total | 99 | 100.0% |
The antimicrobial resistance pattern against the medications including specific antimicrobial resistance patterns against Gram-negative uropathogens.
| Medications | Total/Resistant |
|
|
|
|
|---|---|---|---|---|---|
| Cephazolin | 25 (96%) | 85.7% | 100% | 100% | 100% |
| Cefotaxime | 24 (79.2%) | 66.6% | 100% | 50% | 100% |
| Cefoxitin | 41 (70.7%) | 50% | 71.4% | 75% | 100% |
| Cefuroxime | 46 (93.5%) | 100% | 85.7% | 85.7% | 100% |
| Ceftriaxone | 7 (85.7%) | 100% | 100% | 100% | |
| Ceftazidime | 26 (53.8%) | 53.8% | 50% | ||
| Cefepime | 20 (85%) | 81.8% | 100% | ||
| Cefixime | 20 (55%) | 66% | 60% | 30% | 100% |
| Ampicillin | 53 (94.3%) | 100% | 100% | 100% | 100% |
| Cefoperazone–sulbactam | 49 (30.6%) | 6.6% | 60% | 0% | 100% |
| Amoxicillin–clavulanic acid | 40 (75%) | 53.3% | 85.7% | 88.9% | 100% |
| Gentamicin | 54 (59.3%) | 61.5% | 71.4% | 45.5% | 100% |
| Amikacin | 63 (27%) | 0% | 0% | 20% | 73.6% |
| SMX-TMP | 53 (84.9%) | 91% | 77.7% | 89% | 100% |
| Ciprofloxacin | 65 (58.5%) | 68.7% | 50% | 14.3% | 94.1% |
| Levofloxacin | 28 (42.8) | 52.4% | 66.6% | 100% | |
| Nitrofurantoin | 3 (100%) | ||||
| Fosfomycin | 3 (33.3%) | ||||
| Imipenem | 54 (35.3%) | 7.1% | 11.1% | 15.4% | 92.8% |
| Meropenem | 46 (54.3%) | 10% | 57.1% | 50% | 93.7% |
| Ertapenem | 34 (50%) | 30% | 37.5% | 80% | 85.7% |
| Linezolid | 10 (40%) | 8.3% | |||
| Piperacillin | 26 (69.2%) | 20% | 57% | 100% | |
| Piperacillin–tazobactam | 37 (48.6%) | 33% | 25% | 14.3% | 100% |
| Vancomycin | 7 (14,3%) | ||||
| Tigecycline | 26 (7.6%) | 0% | 0% | 10.5% | 0% |
| Colistin | 43 (4.6%) | 0% | 0% | 14% | 4% |
| Daptomycin | 6 (33.3%) | ||||
| Clindamycin | 8 (12.5%) | ||||
| Ampicillin/sulbactam | 7 (14.3%) |